GlassScriptPhysician profile
Thuy Le
NPI 1144683962
$7,513.20
in general payments reported to CMS, 2019-2025
40 companies · $3,668 in 2025
The $3,668 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.57 · 2022: $709 · 2023: $1,460 · 2024: $1,584 · 2025: $3,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,962 · Consulting Fee: $2,345 · Education: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,962.08 |
| Consulting Fee | $2,345.00 |
| Education | $403.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,921.65 | 2022-2025 | Imfinzi, Enhertu |
| Daiichi Sankyo INC. | $580.31 | 2022-2025 | Enhertu, Vanflyta, Injectafer |
| Novartis Pharmaceuticals Corporation | $443.11 | 2022-2025 | Kisqali, Piqray |
| Pfizer INC. | $404.81 | 2023-2025 | |
| Seagen INC. | $312.35 | 2022-2023 | Tukysa, Adcetris |
| Astellas Pharma US INC | $289.16 | 2022-2023 | |
| Lilly USA, LLC | $278.94 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Gilead Sciences, INC. | $277.83 | 2022-2025 | Trodelvy |
| Stemline Therapeutics INC. | $212.99 | 2023-2025 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $205.56 | 2023-2025 | Iclusig, Ninlaro, Fruzaqla |
| Merck Sharp & Dohme LLC | $198.31 | 2022-2025 | Keytruda, Lynparza |
| Siemens Medical Solutions USA, INC. | $159.60 | 2024 | |
| Incyte Corporation | $156.95 | 2021-2025 | Jakafi, Zynyz, Monjuvi |
| Genentech USA, INC. | $147.47 | 2023-2025 | Venclexta, Gazyva, Lunsumio |
| Genzyme Corporation | $92.05 | 2024-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $78.55 | 2022-2023 | Lumakras, Vectibix, Xgeva |
| Puma Biotechnology, INC. | $62.35 | 2023-2025 | |
| Janssen Biotech, INC. | $62.22 | 2023-2025 | Rybrevant, Darzalex, Talvey |
| E.R. Squibb & Sons, L.L.C. | $56.60 | 2022-2025 | Opdivo |
| Adc Therapeutics America, INC. | $54.13 | 2025 | |
| Taiho Oncology, INC. | $50.53 | 2022-2024 | |
| Geron Corporation | $45.47 | 2025 | Rytelo |
| Array Biopharma INC | $39.45 | 2024-2025 | Lorbrena, Mektovi, Braftovi |
| Janssen Scientific Affairs, LLC | $37.31 | 2025 | Rybrevant |
| Exelixis INC. | $36.17 | 2022-2025 | Cabometyx |
| Novocure INC. | $30.04 | 2024 | Optune Lua (Novottf-200t) |
| Caris Mpi, INC. | $29.35 | 2025 | Mi Cancer Seek |
| Abbvie INC. | $29.11 | 2024 | |
| Glaxosmithkline, LLC. | $23.95 | 2024 | Jemperli, Zejula |
| Foundation Medicine, INC. | $22.48 | 2023 | |
| Tolmar, INC. | $22.05 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $22.05 | 2025 | Rubraca |
| Mirati Therapeutics, INC. | $20.35 | 2023 | Krazati |
| Celgene Corporation | $17.74 | 2022 | |
| Kyowa Kirin, INC. | $17.61 | 2023 | Poteligeo |
| Sobi, INC | $15.63 | 2022 | |
| Agios Pharmaceuticals, INC. | $15.43 | 2023 | Pyrukynd |
| G1 Therapeutics, INC. | $14.93 | 2023 | Cosela |
| Regeneron Healthcare Solutions, INC. | $14.58 | 2021 | |
| Emd Serono, INC. | $14.03 | 2023 | Bavencio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thuy Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.